Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 19, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,775,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,250.52 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 453,964,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.15% of total voting rights.
- Shares in Issue: 5,570,764,913 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the open market purchase of 2,775,000 shares. This transaction increased the company's Treasury share count and adjusted the denominator for voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,570,764,913) for accurate calculation of ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (453,964,158) and its impact on the 8.15% voting rights representation.
- Note that this filing is a regulatory disclosure of a share buyback and does not contain operational or financial performance data for the period.